6-K: Q1 2024 Results
AstraZeneca | 6-K: Results of Annual General Meeting Held on 11 April 2024
AstraZeneca | 6-K: AstraZeneca Increases 2024 Dividend by 7%
AstraZeneca | 6-K: Enhertu Approved in the US as First Tumour-agnostic HER2-directed Therapy for Previously Treated Patients with Metastatic HER2-positive solid Tumours
AstraZeneca | 6-K: Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
AstraZeneca | 6-K: Total Voting Rights
AstraZeneca | 6-K: Voydeya Approved in the Us as Add-On Therapy to Ravulizumab or Eculizumab for Treatment of Extravascular Haemolysis in Adults with the Rare Disease PNH
AstraZeneca | 6-K: Datopotamab Deruxtecan Biologics License Application Accepted in the Us for Patients with Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer
AstraZeneca | 6-K: Ultomiris Approved in the Us for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder
AstraZeneca | DFAN14A: Definitive additional proxy soliciting materials filed by non-management
AstraZeneca | F-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
AstraZeneca | 6-K: Astrazeneca to Acquire Fusion to Accelerate the Development of Next-Generation Radioconjugates to Treat Cancer
AstraZeneca | 6-K: AstraZeneca to Acquire Amolyt
AstraZeneca | 6-K: Transaction by Person Discharging Managerial Responsibilities
AstraZeneca | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
AstraZeneca | 6-K: Notice of Annual General Meeting
AstraZeneca | 6-K: Astrazeneca Plc Announced That, On 5 March 2024, An Award of the Company's Ordinary Shares of $0.25 Each Vested to Pascal Soriot, Executive Director and Chief Executive Officer, Under the Terms of the Astrazeneca Deferred Bonus Plan
AstraZeneca | 6-K: Transactions by Persons Discharging Managerial Responsibilities
AstraZeneca | CERT: Others
AstraZeneca | 8-A12B: Registration of a class of securities on a national securities exchange
No Data